MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Compugen Ltd

Fermé

1.69 -5.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.68

Max

1.78

Chiffres clés

By Trading Economics

Revenu

-1.1M

-7.2M

Ventes

813K

2.3M

P/E

Moyenne du Secteur

60.333

40.527

BPA

-0.08

Marge bénéficiaire

-314.405

Employés

74

EBITDA

-912K

-8.4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+293.26% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-520M

166M

Ouverture précédente

6.75

Clôture précédente

1.69

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Compugen Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2025, 23:09 UTC

Résultats

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 juil. 2025, 19:16 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 juil. 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 juil. 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 juil. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

James Hardie Completes Acquisition of AZEK

1 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 juil. 2025, 20:24 UTC

Résultats

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 juil. 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 juil. 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 juil. 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 juil. 2025, 19:01 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 juil. 2025, 18:41 UTC

Acquisitions, Fusions, Rachats

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 juil. 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 juil. 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 juil. 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 juil. 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 juil. 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 juil. 2025, 17:01 UTC

Acquisitions, Fusions, Rachats

Danone Completed Acquisition of Majority Stake in Kate Farms

1 juil. 2025, 16:55 UTC

Résultats

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 juil. 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 juil. 2025, 16:25 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 15:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 juil. 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 juil. 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparaison

Variation de prix

Compugen Ltd prévision

Objectif de Prix

By TipRanks

293.26% hausse

Prévisions sur 12 Mois

Moyen 7 USD  293.26%

Haut 10 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

1.25 / 1.48Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.